Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Cardiology/Vascular Diseases | Trauma (Emergency, Injury, Surgery) | Family Medicine
Disease Category: Heart Attack (Myocardial Infarction)
Location: United States, FL
Clinical Trial Details
Research Study Summary
Translate - Data Registry Study - Prospective, longitudinal, observational study of patients with acute myocardial infarction (AMI) treated with percutaneous coronary intervention (PCI) and ADP receptor inhibitor
The overall goals of TRANSLATE-ACS are to examine in-hospital and longitudinal outcomes of AMI patients managed with PCI, as well as to assess post-discharge care patterns and treatment adherence. In particular, we will examine how physicians are making treatment choices between marketed ADP receptor inhibitors; factors influencing downstream continuation of and adherence to these medications; and real-world effectiveness, safety, and health care costs in a broad-based patient population.
Patient Inclusion Criteria: Adults with NSTEMI, or STEMI, implementing standard clinical, Electrocardiographic and cardiac biomarker criteria (Troponin I > .07 ng/mL), treated with PCI during the MI hospitalization and treated with ADP Receptor Inhibitor (including clopidogrel, prasugrel, ticlopidine, or ticagrelor) during the MI hospitalization and prescribed ADP Receptor Inhibitor at discharge.
Patient Exclusion Criteria:
- Exclude ALL patients participating in clinical trial that specifies ADP Receptor Inhibitor treatment in the next 12 months.
- Patient who is unable to comply with follow up procedures as outlined in study protocol
- Patient who is unsuitable for study participation in the estimation of the Investigator
To Learn more
Both Male and Female
Date Last Changed:
July 19, 2013
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these